For years, Dupixent (dupilumab) has been hailed as a breakthrough for those suffering from moderate-to-severe eczema (atopic dermatitis) and asthma. However, a growing number of legal claims and scientific studies have raised concerns about a potential connection between the drug and a rare form of blood cancer known as Cutaneous T-Cell Lymphoma (CTCL).
As of early 2026, the legal landscape is shifting. If you or a loved one are using Dupixent, here is the essential information regarding current lawsuits and the medical concerns at the heart of the litigation.
The Core of the Controversy: CTCL and “Unmasking”
The primary concern involves Cutaneous T-Cell Lymphoma (CTCL), a rare cancer that begins in the white blood cells and attacks the skin. Because CTCL often presents as red, scaly, and itchy rashes, it is frequently misdiagnosed as severe eczema—the very condition Dupixent is prescribed to treat.
Lawsuits against the manufacturers, Sanofi and Regeneron, generally center on two allegations:
- Failure to Warn: Plaintiffs argue that the manufacturers knew or should have known about the increased risk of lymphoma but failed to provide adequate warnings to doctors and patients.
- Unmasking or Acceleration: Some medical experts suggest that Dupixent’s impact on the immune system may “unmask” or rapidly accelerate a pre-existing, undiagnosed case of CTCL, causing it to become more aggressive.
Current Status of Dupixent Lawsuits (2026)
As of January 2026, litigation is in its early stages. While there is currently no massive “class action” settlement, the following updates are critical:
- Individual Filings: Lawsuits are being filed in various U.S. District Courts. For example, a significant wrongful death case was filed in late 2025 involving a patient who was diagnosed with CTCL shortly after starting treatment.
- MDL Consolidation: While a Multidistrict Litigation (MDL) has not yet been officially formed, legal experts anticipate that individual cases may soon be consolidated to streamline the discovery process.
- FDA Monitoring: The FDA has issued safety alerts regarding these reports, and researchers continue to investigate whether the drug directly contributes to cancer or simply hides the symptoms of an underlying condition.
Symptoms to Watch For
Because the symptoms of CTCL and eczema are so similar, patients are encouraged to monitor their skin closely. Signs that may indicate something more serious than a standard flare-up include:
- Persistent red, scaly patches that do not respond to treatment.
- The appearance of thickened or raised skin plaques.
- Mushroom-like tumors or lumps on the skin.
- Significantly enlarged or swollen lymph nodes.
- Intense itching that feels different from previous eczema symptoms.
Who is Eligible to File a Claim?
While every law firm has different criteria, currently the Ochs Law Firm is reviewing cases for individuals who:
- Were prescribed and used Dupixent for at least three months.
- Were diagnosed with CTCL, Mycosis Fungoides, or Sézary Syndrome after starting the medication.
- Had no prior history of Hodgkin’s or non-Hodgkin lymphoma before using the drug.
Important Note: If you are currently taking Dupixent, do not stop your medication without consulting your healthcare provider first. Abruptly stopping a biologic can lead to severe symptom rebounds.
